NIH Trial Underway for Universal Flu Vaccine

WEDNESDAY, July 13, 2022 (HealthDay News) -- The National Institutes of Health Clinical Center has begun a phase I trial of a potential universal influenza vaccine, according to an announcement by the agency.
The National Institute of Allergy and Infectious Diseases recently began enrolling 100 adults (aged 18 to 55 years) for the single-site trial. Volunteers will be randomly assigned (1:1:1) to receive two doses of placebo or vaccine spaced 28 days apart. Group A will receive BPL-1357 intramuscularly along with intranasal saline placebo. Group B will receive doses of the candidate vaccine intranasally along with intramuscular placebo. Group C will receive intramuscularly and intranasally delivered placebo at both visits.
BPL-1357 is a whole-virus vaccine consisting of four strains of noninfectious, chemically inactivated, low-pathogenicity avian flu virus. Volunteers will return to the clinic seven times to provide blood and nasal mucosal samples to detect and characterize immune responses.
"Influenza vaccines that can provide long-lasting protection against a wide range of seasonal influenza viruses as well as those with pandemic potential would be invaluable public health tools," Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases, said in a statement.
Related Posts
Phthalate Exposure May Increase Diabetes Risk in Women
TUESDAY, Feb. 14, 2023 (HealthDay News) -- Certain phthalate metabolites are...
Intraoperative Staff Turnover Linked to Procedural Inefficiency
MONDAY, March 27, 2023 (HealthDay News) -- Turnover among operative staff is...
History of Neurodevelopmental Disorders Linked to Seminoma
WEDNESDAY, May 10, 2023 (HealthDay News) -- Having a history of...
Pasos para una larga vida: una breve caminata diaria ayuda a las personas mayores de 85 años
JUEVES, 25 de agosto de 2022 (HealthDay News) -- Nunca es demasiado tarde para...